Drug Profile
LNA 043
Alternative Names: LNA-043Latest Information Update: 12 Oct 2022
Price :
$50
*
At a glance
- Originator Novartis
- Class Anti-inflammatories; Antirheumatics
- Mechanism of Action Angiogenic protein replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase II Osteoarthritis
Most Recent Events
- 06 Sep 2022 Novartis Pharma completes a phase II trial in Osteoarthritis in Sweden, Czech Republic, Denmark and USA (Intra-articular) (NCT03275064), (EudraCT2016-004052-30)
- 08 Feb 2022 Phase-II clinical trials in Osteoarthritis (Combination therapy) in Switzerland (Intra-articular) (Novartis pipeline, February 2022)
- 26 Oct 2021 LNA 043 receives Fast Track designation for Osteoarthritis in USA [Intra-articular]